Detalhe da pesquisa
1.
Circulating tumor DNA in advanced solid tumors: Clinical relevance and future directions.
CA Cancer J Clin
; 71(2): 176-190, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33165928
2.
Real-World Clinical Performance of a DNA-Based Comprehensive Genomic Profiling Assay for Detecting Targetable Fusions in Nonsquamous NSCLC.
Oncologist
; 2024 Feb 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-38401173
3.
Liquid biopsy-based circulating tumour (ct)DNA analysis of a spectrum of myeloid and lymphoid malignancies yields clinically actionable results.
Histopathology
; 84(7): 1224-1237, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38422618
4.
BRAF V600E and RNF43 Co-mutations Predict Patient Outcomes With Targeted Therapies in Real-World Cases of Colorectal Cancer.
Oncologist
; 28(3): e171-e174, 2023 03 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-36779536
5.
Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer.
N Engl J Med
; 383(9): 813-824, 2020 08 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-32846060
6.
Clinical and pathological features associated with circulating tumor DNA content in real-world patients with metastatic prostate cancer.
Prostate
; 82(7): 867-875, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35286728
7.
Real-World Comprehensive Genomic Profiling Success Rates in Tissue and Liquid Prostate Carcinoma Specimens.
Oncologist
; 27(12): e970-e972, 2022 12 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36069892
8.
Activating IGF1R hotspot non-frameshift insertions define a novel, potentially targetable molecular subtype of adenoid cystic carcinoma.
Mod Pathol
; 35(11): 1618-1623, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35970994
9.
Contrasting genomic profiles from metastatic sites, primary tumors, and liquid biopsies of advanced prostate cancer.
Cancer
; 127(24): 4557-4564, 2021 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34379803
10.
Comparative Genomic Analysis of Intrahepatic Cholangiocarcinoma: Biopsy Type, Ancestry, and Testing Patterns.
Oncologist
; 26(9): 787-796, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34080753
11.
Comparing RECIST 1.1 and iRECIST in advanced melanoma patients treated with pembrolizumab in a phase II clinical trial.
Eur Radiol
; 31(4): 1853-1862, 2021 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-32995974
12.
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study.
Lancet Oncol
; 21(3): 373-386, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32027846
13.
Rociletinib in EGFR-mutated non-small-cell lung cancer.
N Engl J Med
; 372(18): 1700-9, 2015 Apr 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-25923550
14.
Anaphylaxis and systemic mastocytosis controlled with KIT inhibitors in a patient with metastatic lung adenocarcinoma.
Ann Allergy Asthma Immunol
; 131(5): 668-670, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37597693
15.
Activity of erlotinib when dosed below the maximum tolerated dose for EGFR-mutant lung cancer: Implications for targeted therapy development.
Cancer
; 122(22): 3456-3463, 2016 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-27525836
16.
Delay of treatment change after objective progression on first-line erlotinib in epidermal growth factor receptor-mutant lung cancer.
Cancer
; 121(15): 2570-7, 2015 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-25876525
17.
State of the Science and Future Directions for Liquid Biopsies in Drug Development.
Oncologist
; 25(9): 730-732, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32510742
18.
Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial.
Lancet Oncol
; 15(13): 1433-1441, 2014 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-25456362
19.
Management of acquired resistance to epidermal growth factor receptor kinase inhibitors in patients with advanced non-small cell lung cancer.
Cancer
; 120(15): 2289-98, 2014 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-24752335
20.
Real-World Genomic Profile of EGFR Second-Site Mutations and Other Osimertinib Resistance Mechanisms and Clinical Landscape of NSCLC Post-Osimertinib.
J Thorac Oncol
; 19(2): 227-239, 2024 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-37806383